One of the big surprises at the annual meeting of the American Association for Cancer Research last weekend belonged to none other than Eli Lilly, which will soon be able to add another therapy to its list of Phase III assets in the clinic.

…read more

Source: Lilly preps a PhIII study as breast cancer drug race heats up


0 No comments